SCHEMBL282188

SCHEMBL282188

CS(=O)(=O)c1ccc(N)cc1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.62
CYP3A4 P08684 4/20 0.52
TSHR P16473 2/20 0.52
ALDH1A1 P00352 2/20 0.52
THRB P10828 1/20 0.52
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
CASP1 P29466 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
HSD11B1 P28845 1/20 0.48
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
GRM4 Q14833 1/20 0.40
CA12 O43570 1/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30431062 1.00 L3MBTL1 (0.62) L3MBTL1CYP3A4TSHRALDH1A1THRB
SCHEMBL31623389 0.85 L3MBTL1 (0.59) L3MBTL1CYP3A4TSHRALDH1A1THRB
SCHEMBL10184964 0.85 L3MBTL1 (0.59) L3MBTL1CYP3A4TSHRALDH1A1THRB
SCHEMBL18768010 0.83 CYP3A4 (0.52) L3MBTL1CYP3A4TSHRALDH1A1THRB
SCHEMBL1300150 0.83 CYP3A4 (0.55) L3MBTL1CYP3A4TSHRALDH1A1THRB
SCHEMBL7841874 0.82 L3MBTL1 (0.44) L3MBTL1CYP3A4TSHRALDH1A1THRB
SCHEMBL1383117 0.81 CA1 (0.55) L3MBTL1CYP3A4TSHRALDH1A1THRB
SCHEMBL31618992 0.79 CYP3A4 (0.52) L3MBTL1CYP3A4TSHRALDH1A1THRB
SCHEMBL176801 0.79 ALDH1A1 (0.62) L3MBTL1CYP3A4TSHRALDH1A1THRB
SCHEMBL31650697 0.79 ALDH1A1 (0.62) L3MBTL1CYP3A4TSHRALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4703649-B2 2011-06-15 JP claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
US-20240270699-A1 COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS LOMOND THERAPEUTICS, INC. 2024-08-15 US disclosed
EP-4368618-A1 SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF Betta Pharmaceuticals Co., Ltd (CN) 2024-05-15 EP disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
WO-2023043630-A1 COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS LOMOND THERAPEUTICS, INC. (US) 2023-03-23 WO disclosed
WO-2023279986-A1 SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF 贝达药业股份有限公司 2023-01-12 WO disclosed
WO-2023279986-A1 SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF 贝达药业股份有限公司 2023-01-12 WO disclosed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
WO-2000034238-A1 THIOUREA INHIBITORS OF HERPES VIRUSES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed
WO-2000034260-A2 ALPHA-METHYLBENZYL-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A PHENYLENEDIAMINE GROUP AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed
WO-2000034261-A2 HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A SUBSTITUTED PHENYLENEDIAMINE GROUP AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed
WO-2000034269-A1 THIOUREA INHIBITORS OF HERPES VIRUSES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed
WO-1999064415-A1 SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 1999-12-16 WO disclosed
US-5106960-A Fiber-reactive and monoazo red and yellow dyes; color- and washfastness; formaldehyde-resistance; brightness CIBA-GEIGY CORPORATION (US) 1992-04-21 US disclosed
EP-0039306-B1 AZO DYESTUFFS, METHODS FOR THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1984-01-11 EP disclosed
EP-0039306-A1 Azo dyestuffs, methods for their preparation and their use CIBA-GEIGY AG (CH) 1981-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270699-A1 COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS IRAK3, IRAK1, IRAK2 L3MBTL1 912/4885CYP3A4 3456/4885TSHR 2092/4885
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 L3MBTL1 1424/4885CYP3A4 4275/4885TSHR 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.